Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atrium TherapeuticsRNA -3.53%12 Equity-to-Asset is 0.80 as of Mar. 2026, which is 7% above its 10-year median of 0.75. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Atrium Therapeutics ranks better than 65.98% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Atrium Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $234.10 Mil. Atrium Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $292.36 Mil.
Therefore, Atrium Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.80.
The historical rank and industry rank for Atrium Therapeutics's Equity-to-Asset or its related term are showing as below:
RNA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -8.5 Med: 0.75 Max: 0.8
Current: 0.8
During the past 3 years, the highest Equity to Asset Ratio of Atrium Therapeutics was 0.80. The lowest was -8.50. And the median was 0.75.
RNA's Equity-to-Asset is ranked better than 65.98% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs RNA: 0.80
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Atrium Therapeutics Equity-to-Asset Related Terms
Atrium Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNA vs CNTN, QTTB, TARA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Atrium Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Atrium Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrium Therapeutics (RNA) has a Equity-to-Asset of 0.80 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Atrium Therapeutics and its competitors. This is near median its historical median of 0.75. According to the industry distribution chart, Atrium Therapeutics ranks #482 out of 1417 companies in the Biotechnology industry, placing it in the top 34%.
Is Atrium Therapeutics' Equity-to-Asset too high?
Atrium Therapeutics' current Equity-to-Asset of 0.80 is near median its 10-year median of 0.75. The Biotechnology industry median Equity-to-Asset is 0.68. Atrium Therapeutics' value of 0.80 is 17.6% above this industry median. Based on the distribution chart, Atrium Therapeutics ranks #482 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Equity-to-Asset compare to CNTN and QTTB?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #482 out of 1417 companies for Equity-to-Asset. This puts Atrium Therapeutics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Atrium Therapeutics' value of 0.80 is 17.6% above this benchmark. While the company's 10-year median is 0.75 vs. the industry median of 0.68, Atrium Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrium Therapeutics's current Equity-to-Asset of 0.80 is 17.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Atrium Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrium Therapeutics's current Equity-to-Asset is 0.80, which is near median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Equity-to-Asset of 0.80. The current Equity-to-Asset is 0.80, which is near median its 10-year median of 0.75 and 17.6% above the Biotechnology industry median of 0.68. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Equity-to-Asset is 0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 
